扫码登录小狗阅读
-
TRAF3功能缺失揭示了非典型NF-κB通路作为弥漫性大B细胞淋巴瘤的治疗靶点
TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma
From：PNAS Date：2024-04-30
IF：9.4 类型：基础
Read：29 Author：Michael Y Li
-
胎盘循环T细胞：一种新型同种异体CAR-T细胞平台，与成人PBMC衍生的CAR-T相比，具有保留的T细胞干性、更有利的细胞因子谱和持久的疗效
Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T
From：J Immunother Cancer Date：2024-04-29
IF：10.3 类型：基础
Read：12 Author：Natalia Ruggeri Barbaro
-
鼻窦腺癌中Hedgehog通路表达的初步免疫组织化学研究
A Pilot Immunohistochemical Study Identifies Hedgehog Pathway Expression in Sinonasal Adenocarcinoma
From：Int J Mol Sci Date：2024-04-24
IF：4.9 类型：基础
Read：8 Author：Matko Leović
-
表达免疫检查点抑制剂的慢病毒载体可抑制临床前癌症模型中的肿瘤生长
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models
From：J Immunother Cancer Date：2024-04-24
IF：10.3 类型：临床
Read：5 Author：Takuya Tada
-
乐伐替尼计划性药物假期治疗分化型甲状腺癌的疗效：一项前瞻性队列研究
A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer
From：Thyroid Date：2024-04-17
IF：5.8 类型：临床
Read：6 Author：Makoto Tahara
-
埃罗妥珠单抗与自体干细胞移植和来那度胺用于治疗多发性骨髓瘤的I期临床研究
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
From：J Immunother Cancer Date：2024-04-12
IF：10.3 类型：临床
Read：7 Author：David G Coffey
-
纳武单抗和补救性纳武单抗/伊匹单抗治疗晚期肾透明细胞癌II期研究的无治疗生存期（HCRN GU16-260-队列A）
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
From：J Immunother Cancer Date：2024-04-11
IF：10.3 类型：临床
Read：4 Author：Michael B Atkins
-
晚期雌激素受体阳性乳腺癌中靶向PI3K-AKT和mTOR的最佳治疗
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
From：Lancet Oncol Date：2024-04-01
IF：41.6 类型：综述
Read：17 Author：Iseult M Browne
-
卡博替尼加阿特珠单抗与索拉非尼治疗晚期肝细胞癌的比较（COSMIC-312）：随机3期研究的最终结果
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
From：Lancet Gastroenterol Hepatol Date：2024-04-01
IF：35.6 类型：临床
Read：44 Author：Thomas Yau
-
老年晚期非小细胞肺癌患者的免疫治疗或化免治疗
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
From：JAMA Oncol Date：2024-03-27
IF：22.4 类型：临床
Read：13 Author：Yoko Tsukita
-
瑞波西利联合内分泌疗法用于早期乳腺癌
Ribociclib plus Endocrine Therapy in Early Breast Cancer
From：N Engl J Med Date：2024-03-21
IF：96.1 类型：临床
Read：14 Author：Dennis Slamo
-
三阴性乳腺癌中Gab1信号失调
Dysregulated Gab1 signalling in triple negative breast cancer
From：Cell Commun Signal Date：2024-03-06
IF：8.1 类型：基础
Read：3 Author：Hannes Bongartz
-
新冠肺炎大流行期间高危胃肠癌患者的生存率
Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic
From：JAMA Netw Open Date：2024-03-04
IF：10.5 类型：临床
Read：4 Author：Lauren M Janczewski
-
缺失线粒体丙酮酸载体1支持卵巢癌中脯氨酸依赖性增殖和胶原生物合成
Loss of mitochondrial pyruvate carrier 1 supports proline-dependent proliferation and collagen biosynthesis in ovarian cancer
From：Mol Metab Date：2024-03-01
IF：6.9 类型：基础
Read：5 Author：M Rufaik Farook
-
来那度胺暴露患者接受既往治疗后，达雷木单抗联合伊沙佐米和地塞米松的疗效和安全性：DARIA 2期研究的最终结果
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
From：10.1 Date：2024-03-01
IF：0.0 类型：临床
Read：2 Author：Evangelos Terpos
-
一线使用德瓦鲁单抗治疗PD-L1阳性、PS2、晚期非小细胞肺癌（NSCLC）患者：多中心、单臂、II期试验SAKK 19/17的主要分析
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
From：Eur J Cancer Date：2024-03-01
IF：8.4 类型：临床
Read：29 Author：Michael Mark
-
ES-SCLC一线治疗的最新进展和未来策略
Recent advances and future strategies in first-line treatment of ES-SCLC
From：Eur J Cancer Date：2024-03-01
IF：8.4 类型：综述
Read：26 Author：Igor Gomez-Randulfe
-
急性髓性白血病中的γδT细胞：生物学和新兴治疗策略
Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
From：J Immunother Cancer Date：2024-02-27
IF：10.8 类型：综述
Read：7 Author：Adishwar Rao
-
自然杀伤（NK）细胞中基于免疫受体酪氨酸激活基序（ITAM）的受体
ITAM- based receptors in natural killer cells
From：Immunol Rev Date：2024-02-27
IF：8.6 类型：综述
Read：4 Author：Oscar A Aguilar
-
ATRi（Ceralasertib）通过调节肿瘤微环境增强肿瘤检查点免疫治疗
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
From：Nat Commun Date：2024-02-24
IF：16.6 类型：基础
Read：21 Author：Elizabeth L Hardaker
